Skip to main content

Table 3 Univariate analysis according to baseline clinical parameters

From: Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer

  

OS, mo*

95% CI

P

Previous gastrectomy

No

10.9

8.8-13.1

.001

 

Yes

13.9

12.5-15.4

 

Gender

Male

13.3

11.8-14.7

.315

 

Female

11.8

9.5-14.2

 

Age

<median

11.8

10.3 - 13.4

.279

 

≥median

13.4

11.3 - 15.4

 

Performance status

0 or 1

13.3

11.9 - 14.6

<.001

 

≥2

5.9

1.0 - 10.8

 

Hemoglobin

<10 g/dL

7.9

6.0 - 9.8

<.001

 

≥10 g/dL

13.4

10.3 - 16.4

 

No. of involved site(s)

1

12.8

11.4 - 14.3

.048

 

≥2

8.5

6.7 - 10.3

 

Liver metastasis

No

12.2

10.4 - 14.1

.654

 

Yes

12.2

9.5 - 14.8

 

Bone metastasis

No

12.6

10.7 - 14.2

.144

 

Yes

8.2

6.5 - 9.5

 

Peritoneal dissemination

No

13.9

12.4 - 15.4

.008

 

Yes

10.6

8.4 - 12.7

 

Weight loss

No

12.6

10.8 - 14.4

.580

 

Yes

12.0

9.6 - 14.3

 

Chemotherapy

XP

11.2

6.7 - 15.7

.673

 

SP

13.3

11.7 - 14.8

 
 

DP

12.0

8.6 - 15.4

 
 

FP

11.3

7.1 - 15.5

 
  1. * OS, median overall survival; 95% CI, 95% confidence interval.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us